Sunrise Medical Laboratories, Inc

  • Cytotechnologist

    Job Location US-VA-Chantilly
  • Overview

    Responsible for the cytological examination of gyn specimens which includes initial screening and reporting of normal and abnormal cases.  Retrieves previous histories to refer cases for QC review.   Refers all abnormal cases for final pathology review and diagnosis. Adheres to departmental policies and procedures to include departmental programs, quality control, quality assurance and safety. 


    • Utilizes technical skills and abilities to perform cytological screening and review slides.
    • Performs routine screening consistent with the department’s quality and productivity metrics
    • Examines prepared slides with the microscope to detect evidence of abnormalities in gyn cases.
    • Uses diagnostic codes to report negative cases and refers abnormal cases to the pathologists for review.
    • Follows laboratory procedures for slide handling, reviewing, reporting and maintaining records of patient results. 
    • Understands and operates instrumentation systems proficiently.


    • BS Degree in Cytotechnology, Medical Technology, Clinical Laboratory Science or completion of a one year course of study at an accredited school of Cytotechnology.
    • ThinPrep certification required.
    • SurePath certification preferred.
    • Certified in the area of Cytotechnology by the American Society of Clinical Pathologists (ASCP) or ASCP eligible preferred.

    All qualified applicants will receive consideration for employment and will not be discriminated against on the basis of race, color, religion, sex, sexual orientation, gender identity, national origin, age, disability, or protected veteran status. Sunrise Medical Laboratories takes affirmative action in support of its policy to and advance in employment individuals who are minorities, women, protected veterans, and individuals with disabilities


    Sorry the Share function is not working properly at this moment. Please refresh the page and try again later.
    Share on your newsfeed